Nifty
Sensex
:
:
10906.95
36386.61
1.75 (0.02%)
12.53 (0.03%)

Pharmaceuticals & Drugs

Rating :
58/99  (View)

BSE: 500124 | NSE: DRREDDY

2596.80
-22.35 (-0.85%)
18-Jan-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2605.00
  •  2629.35
  •  2594.50
  •  2619.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  536273
  •  13925.94
  •  2749.95
  •  1887.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 43,158.39
  • 27.50
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 47,965.99
  • 0.77%
  • 3.29

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.77%
  • 3.31%
  • 8.17%
  • FII
  • DII
  • Others
  • 0.22%
  • 15.74%
  • 45.79%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.54
  • 1.26
  • -2.84

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.00
  • -6.27
  • -8.09

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.11
  • -14.21
  • -24.35

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.41
  • 28.27
  • 33.58

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.87
  • 4.46
  • 3.62

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.95
  • 17.58
  • 17.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
3,817.50
3,559.80
7.24%
3,736.50
3,333.20
12.10%
3,553.90
3,611.90
-1.61%
3,834.10
3,723.20
2.98%
Expenses
3,058.20
2,890.40
5.81%
2,967.70
3,010.00
-1.41%
2,990.30
3,021.40
-1.03%
3,041.40
2,858.70
6.39%
EBITDA
759.30
669.40
13.43%
768.80
323.20
137.87%
563.60
590.50
-4.56%
792.70
864.50
-8.31%
EBIDTM
19.89%
18.80%
20.58%
9.70%
15.86%
16.35%
20.68%
23.22%
Other Income
128.20
31.60
305.70%
50.40
38.00
32.63%
44.90
20.50
119.02%
43.00
40.30
6.70%
Interest
20.80
22.30
-6.73%
19.50
21.50
-9.30%
17.80
19.60
-9.18%
17.20
16.40
4.88%
Depreciation
278.60
270.20
3.11%
278.70
259.20
7.52%
276.30
254.30
8.65%
271.50
266.50
1.88%
PBT
588.10
408.50
43.97%
521.00
80.50
547.20%
314.40
337.10
-6.73%
547.00
621.90
-12.04%
Tax
80.70
112.30
-28.14%
53.20
23.70
124.47%
49.20
9.70
407.22%
252.80
138.50
82.53%
PAT
507.40
296.20
71.30%
467.80
56.80
723.59%
265.20
327.40
-19.00%
294.20
483.40
-39.14%
PATM
13.29%
8.32%
12.52%
1.70%
7.46%
9.06%
7.67%
12.98%
EPS
31.22
18.42
69.49%
28.68
4.02
613.43%
16.39
20.36
-19.50%
18.26
29.69
-38.50%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
14,942.00
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
6,900.60
Net Sales Growth
5.02%
0.60%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
1.28%
 
Cost Of Goods Sold
4,100.00
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
1,940.40
Gross Profit
10,842.00
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
4,960.20
GP Margin
72.56%
71.71%
73.96%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
71.88%
Total Expenditure
12,057.60
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
5,587.60
Power & Fuel Cost
-
329.30
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
122.70
% Of Sales
-
2.31%
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
1.78%
Employee Cost
-
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
992.00
% Of Sales
-
22.51%
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
14.38%
Manufacturing Exp.
-
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
1,115.30
% Of Sales
-
12.23%
13.29%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
16.16%
General & Admin Exp.
-
1,198.90
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
582.30
% Of Sales
-
8.40%
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
8.44%
Selling & Distn. Exp.
-
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
651.30
% Of Sales
-
9.31%
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
9.44%
Miscellaneous Exp.
-
70.50
70.60
483.00
65.70
35.60
38.50
85.20
147.00
150.80
651.30
% Of Sales
-
0.49%
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
2.66%
EBITDA
2,884.40
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
1,313.00
EBITDA Margin
19.30%
16.46%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
19.03%
Other Income
266.50
155.20
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
99.40
Interest
75.30
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
108.20
Depreciation
1,105.10
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
497.70
PBT
1,970.50
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
806.50
Tax
435.90
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
260.80
Tax Rate
22.12%
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
-39.74%
PAT
1,534.60
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
PAT before Minority Interest
1,534.60
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
10.27%
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
-13.29%
PAT Growth
31.86%
-27.43%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
138.33%
 
Unadjusted EPS
94.55
57.08
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83
-54.48

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
3,526.10
Share Capital
83.00
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
84.20
Total Reserves
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
3,403.00
Non-Current Liabilities
2,538.40
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
2,051.40
Secured Loans
63.00
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
38.60
Unsecured Loans
2,445.90
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
1,959.00
Long Term Provisions
81.70
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
0.00
Current Liabilities
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
1,711.20
Trade Payables
1,334.50
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
1,505.60
Other Current Liabilities
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
6.20
Short Term Borrowings
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
0.00
Short Term Provisions
591.70
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
199.40
Total Liabilities
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
Net Block
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
2,927.00
Gross Block
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
6,502.70
Accumulated Depreciation
10,463.00
9,001.70
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
2,112.90
Non Current Assets
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
3,357.20
Capital Work in Progress
3,470.50
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
429.60
Non Current Investment
465.30
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
0.60
Long Term Loans & Adv.
564.80
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
0.00
Other Non Current Assets
36.80
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
0.00
Current Assets
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
3,931.50
Current Investments
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
51.70
Inventories
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
1,325.00
Sundry Debtors
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
1,440.60
Cash & Bank
263.80
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
562.30
Other Current Assets
1,440.00
451.50
393.10
226.20
1,214.60
961.90
705.80
879.60
660.90
551.90
Short Term Loans & Adv.
958.30
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
551.20
Net Current Assets
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
2,220.30
Total Assets
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
599.10
PBT
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
-656.30
Adjustment
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
2,080.10
Changes in Working Capital
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
-545.60
Cash after chg. in Working capital
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
878.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-276.10
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
-279.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
-505.00
Net Fixed Assets
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
-571.80
Net Investments
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
226.80
Others
-270.50
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
-160.00
Cash from Financing Activity
-444.00
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
-265.10
Net Cash Inflow / Outflow
-129.30
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
-171.00
Opening Cash & Equivalents
377.80
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
744.70
Closing Cash & Equivalent
254.20
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00
562.30

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
752.35
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
207.08
ROA
4.23%
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
-12.24%
ROE
7.40%
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
-23.07%
ROCE
8.21%
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
-9.14%
Fixed Asset Turnover
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
1.16
Receivable days
100.33
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
55.01
Inventory Days
73.63
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
63.79
Payable days
37.10
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
85.61
Cash Conversion Cycle
136.86
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
33.19
Total Debt/Equity
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
0.57
Interest Cover
18.14
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06
-5.07

Annual Reports:


News Update


  • USFDA completes inspection at Dr. Reddy's Srikakulum Plant
    16th Jan 2019, 09:07 AM

    The company has been issued a Form 483 with 4 observations

    Read More
  • Dr. Reddy's launches Sevelamer Carbonate for Oral Suspension in US Market
    27th Dec 2018, 11:39 AM

    Dr. Reddy's Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90

    Read More
  • Dr. Reddy's launches Aspirin, Dipyridamole Capsules in US Market
    24th Dec 2018, 11:18 AM

    Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size

    Read More
  • Dr. Reddy's launches Omeprazole Delayed-Release Tablets
    11th Dec 2018, 10:33 AM

    OTC Omeprazole Delayed-Release Tablets, 20 mg, is a proton pump inhibitor used to treat frequent heartburn occurring two or more days per week in adults

    Read More
  • Dr. Reddy's launches Chlorthalidone Tablets in US Market
    28th Nov 2018, 10:56 AM

    Dr. Reddy's Chlorthalidone Tablets, USP are available in 25 mg tablets in the bottle-count sizes of 100 and 1000, and 50 mg tablets in the bottle-count size of 100

    Read More
  • USFDA completes audit of Dr. Reddy’s Andhra Pradesh facility
    19th Nov 2018, 10:33 AM

    The USFDA has completed audit on November 16, 2018 with zero observations

    Read More
  • German regulator concludes audit of Dr Reddy’s Vishakapatnam facility
    12th Nov 2018, 12:24 PM

    The facility is considered compliant and the EU-GMP certification continues to remain active with one specific exclusion of a new product

    Read More
  • Dr. Reddy's Lab launches Atomoxetine Capsules in US market
    31st Oct 2018, 12:09 PM

    The Strattera brand and generic had US sales of approximately $304 million MAT for the most recent twelve months ending in August 2018

    Read More
  • USFDA issues eight observations for Dr. Reddy's Duvvada plant
    31st Oct 2018, 10:11 AM

    A Form 483 is issued to a firm's management at the conclusion of an inspection

    Read More
  • Dr. Reddy’s Laboratories Q2 consolidated net profit climbs 70%
    26th Oct 2018, 15:16 PM

    Total consolidated income of the company increased by 9.87% at Rs 3,945.70 crore for Q2FY19

    Read More
  • Dr. Reddys Lab - Quarterly Results
    26th Oct 2018, 14:52 PM

    Read More
  • Dr. Reddy's Lab gets approval for Aspirin, extended-release Dipyridamole Capsules
    15th Oct 2018, 14:53 PM

    The Aggrenox brand and generic had US sales of around $183 million MAT

    Read More
  • Dr. Reddy’s Lab sells Jeedimetla API manufacturing business unit to Therapiva
    15th Oct 2018, 09:34 AM

    This divestiture is being done by way of slump sale and includes all related fixed assets current assets, current liabilities, and its employees

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.